Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622636 | 1.00 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL202927 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL29467174 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL3688848 | 0.80 | MAPT (0.47) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL8075138 | 0.78 | ALDH1A1 (0.45) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL8561095 | 0.78 | MEN1 (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL18486948 | 0.78 | KMT2A (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL4064206 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL414810 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL5126783 | 0.77 | PKM (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-110218179-B | Preparation method of 4-amino-2-chloro-3-nitropyridine | 新发药业有限公司 | 2020-08-04 | — | — | CN | claimed |
| US-3933498-A | Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-20 | — | — | US | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4531838-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | Kuda Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025061177-A1 | SMALL-MOLECULE DRUG FOR TREATING CGRP-RELATED DISORDER | 成都康弘药业集团股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-119661518-A | Small molecule medicine for treating CGRP related disorder | 成都康弘药业集团股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240424614-A1 | METAL PASTE FOR BONDING, AND BONDED BODY AND METHOD FOR PRODUCING SAME | RESONAC CORPORATION (JP) | 2024-12-26 | — | — | US | disclosed |
| CN-1678612-A | virus inhibitor | LEUVEN K U RES & DEV (BE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1569936-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
| US-5217982-A | Compounds having antihypertensive properties | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-3933498-A | Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MEN1 2337/4885KMT2A 133/4885USP2 2477/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | MEN1 2829/4885KMT2A 461/4885USP2 1814/4885 |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | MEN1 3264/4885KMT2A 2970/4885USP2 2598/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | MEN1 3685/4885KMT2A 2492/4885USP2 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.